LIFE CELL LAUNCHES ‘TRANSFORMATIONAL’ NEW BORN SCREENING PROGRAM
24 Nov 2018
LifeCell International, India’s premier stem cell bank and mother & baby diagnostics company today announced the launch of “RightStart” – the world’s first Integrated DNA testing for Newborn Screening to detect over 50 medical conditions.
The technology has been proved to be very useful than the other current screening methods and have reduced the number of false positive reports.
In current process of newborn screening, a few drops of blood are obtained through heel prick from the baby’s heel, usually 48 hours after childbirth, and is analysed by profiling a specific set of metabolites present in the blood. If an abnormal metabolic profile is found further testing is recommended for confirmation.
The confirmatory test would need an additional sample to be taken once again from the child. Since most routine screening labs do not have DNA testing capabilities, the child is referred to specialised labs leading to further delays in diagnosis & treatment apart from causing further agony for the parents. The DNA based test, is considered a gold standard and is most reliable for confirmation as it does not get impacted by interferences such as medications, nutrition, temperature, or preterm status.
Ishaan Khanna, CEO of Diagnostic & BioBank Divisions, LifeCell International said “As a leader we always bring the first and best to the country and “RightStart” is another milestone achievement. For the first time over 50 conditions can be tested with ‘RightStart’s integrated DNA testing in the country with a faster throughput and higher accuracy of test results”.